NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

Nycomed RSS Channel

Display # 
Title Published Date
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 18 January 2012
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets 16 June 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Nycomed acquires distribution rights to product portfolio in Turkey 14 April 2011
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment 31 March 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed's novel COPD therapy roflumilast receives FDA approval 01 March 2011
Nycomed to acquire Colombian company Farmacol 06 February 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Nycomed to accelerate expansion in China 01 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® 03 May 2010
Nycomed and Baxter receive FDA approval for TachoSil® 08 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed reports continued satisfactory performance in the third quarter 2009 13 November 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD 11 August 2009

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]